Basic Information
BETMIGA ® PROLONGED-RELEASE TABLETS 50MG
TABLET, FILM COATED, EXTENDED RELEASE
Regulatory Information
SIN14623P
September 15, 2014
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XG04BD12
Company Information
ASTELLAS PHARMA SINGAPORE PTE. LTD.
ASTELLAS PHARMA SINGAPORE PTE. LTD.
Active Ingredients
Strength: 50 mg
Detailed Information
Contraindications
**4.3 Contraindications** Mirabegron is contraindicated in patients with - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. - Severe uncontrolled hypertension defined as systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg.
Indication Information
**4.1 Therapeutic indications** Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.